

2002/11/27

②

XP-002270091 1st)

AN - 1996-017127 [02]

AP - JP19940087012 19940426

CPY - TANA

DC - A96 B07

DR - 2044-U

FS - CPI

IC - A61K9/14 ; A61K31/40 ; A61K31/445 ; A61K47/10 ; A61K47/32 ; A61K47/38

MC - A12-V01 B04-C02 B04-C03 B04-N04 B05-B01B B05-B01P B07-D03 B07-D04D

B10-A07 B10-E04C B10-G02 B10-H01 B10-J02 B12-M11C

M1 - [01] H4 H402 H482 H5 H589 H8 M280 M312 M323 M332 M342 M383 M393 M423

M431 M510 M520 M530 M540 M620 M782 M903 M904 M910 R024 V0 V743;

R02044-M; 2044-U

- [02] M431 M782 M903 M904 R024; R06563-M

M2 - [03] F012 F013 F014 F015 F016 F432 G011 G100 H3 H341 J0 J012 J2 J212

M1 M113 M210 M211 M240 M272 M282 M320 M413 M431 M510 M521 M531 M540

M782 M903 M904 R024; R03027-M

- [04] F012 F013 F014 F015 F423 G010 G017 G100 H5 H543 H7 H720 H8 J5

J522 L9 L930 M1 M123 M129 M132 M139 M210 M211 M272 M283 M311 M322 M343

M413 M431 M510 M521 M532 M540 M782 M903 M904 R024; 9602-11401-M

PA - (TANA) TANABE SEIYAKU CO

PN - JP7291854 A 19951107 DW199602 A61K9/14 016pp

PR - JP19940087012 19940426

XA - C1996-005509

XIC - A61K-009/14 ; A61K-031/40 ; A61K-031/445 ; A61K-047/10 ; A61K-047/32 ;
A61K-047/38

AB - J07291854 Pharmaceutical prepn. comprises a solid disperse system
obtd. by grinding three components of a sparingly soluble drug, a
hydrophilic polymer and solubilising agent in the presence of an aq.
solvent in an amt. not to dissolve the drug completely, and removing
the solvent.

- Also claimed is the prodn. of the prepn.

- Solubilising agent pref. includes polyhydric alcohol, polyhydric
alcohol ether, polyhydric alcohol ester, di- or tribasic acid ester,
lecithin, oligosaccharide, sugar alcohol, aliphatic hydrocarbon and/or
organo Si cpds. Hydrophilic polymer includes hydrophilic carbohydrate,
hydrophilic protein, hydrophilic natural polymer, hydrophilic fatty
acid polyester and/or a polymer comprising hydrophilic ethylenic
unsatd. monomer. Aq. solvent is water and/or an organic solvent
miscible with water. Sparingly soluble drug is
(3E,4E)-3-benzylidene-4-(3,4,5-trimethoxybenzylidene)pyrrolidine-
2,5-dione.

- ADVANTAGE - The prepn. is simply produced without using halogenated
organic solvents. The prepn. is safe.

- In an example, nifedipine (1 pts.wt.) was kneaded with 70-90 deg.C
melted PEG 6000 (1 pts.wt.) to which HPMC (5 pts.wt.) was added and
ground for 10 min. by a vibrating ball mill, and ground for 5 min.
together with water (3 pts.wt.). After drying at 50 deg.C for 8 hrs.,
the mixt. was ground by the ball mill. The obtd. powder was charged
into gelatin capsules to give the prepn.(Dwg.0/10)

CN - R02044-M R06563-M R03027-M 9602-11401-M

DRL - 2044-U

IW - PHARMACEUTICAL PREPARATION IMPROVE SOLUBLE COMPRISE SOLID DISPERSE
SYSTEM OBTAIN GRIND SPARING SOLUBLE DRUG HYDROPHILIC POLYMER SOLUBLE
AGENT PRESENCE AQUEOUS SOLVENT

IKW - PHARMACEUTICAL PREPARATION IMPROVE SOLUBLE COMPRISE SOLID DISPERSE
SYSTEM OBTAIN GRIND SPARING SOLUBLE DRUG HYDROPHILIC POLYMER SOLUBLE
AGENT PRESENCE AQUEOUS SOLVENT

NC - 001

OPD - 1994-04-26

ORD - 1995-11-07

PAW - (TANA) TANABE SEIYAKU CO

TI - Pharmaceutical prepn. with improved solubility - comprises solid
disperse system obtd. by grinding sparingly soluble drug, hydrophilic
polymer and solubilising agent in presence of aq. solvent

A01 - [001] 018 ; P0599 ;

- [002] 018 ; R06563 G3678 G3634 G3623 P0599 D01 D03 D11 D10 D23 D22

D31 D42 D50 F24 F26 F34 H0293 ;

- [003] 018 ; P0839-R F41 D01 D63 ;

- [004] 018 ; ND01 ; Q9999 Q8037 Q7987 ;

- [005] 018 ; B9999 B3407 B3383 B3372 ;

A02 - [001] 018 ; R00351 G1558 D01 D23 D22 D31 D42 D50 D73 D82 F47 ; H0000

; P0055 ; P8004 P0975 P0964 D01 D10 D11 D50 D82 F34 ;

- [002] 018 ; ND01 ; Q9999 Q8037 Q7987 ;

- [003] 018 ; B9999 B5094 B4977 B4740 ;

A03 - [001] 018 ; R24033 G3714 P0599 D01 F70 ;

- [002] 018 ; ND01 ; Q9999 Q8037 Q7987 ;